T2 Biosystems Investment Losses
Have you suffered losses investing in T2 Biosystems? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Dispute Resolution claim against the brokerage firm that sold you the investment.
T2 Biosystems (Nasdaq: TTOO), a biopharmaceutical company, reportedly offers diagnostic instrument for detection of infectious diseases in blood, plasma, serum, saliva, sputum, and urine. The company operates in the United States.
Unfortunately for investors, in the past year, the company’s share price has reportedly declined 64%.
The problem with biopharmaceutical stocks such as T2 Biosystems is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy clinical testing trials that yield specific data. If the expected data or end points are not met, the stock can drop drastically.
Without a strong understanding of the company and its basic operations, investors may be looking at serious losses.
Investigating Potential Claims
The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly recommending high-risk biopharma stocks, like T2 Biosystems to investors.
Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.
If you have concerns regarding investment losses in T2 Biosystems, please call the securities attorneys at The White Law Group for a free consultation at 888-637-5510.
The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.
Tags: T2 Biosystems, T2 Biosystems complaints, T2 Biosystems default, T2 Biosystems help, T2 Biosystems high commissions, T2 Biosystems information, T2 Biosystems investigation, T2 Biosystems investment, T2 Biosystems investment losses, T2 Biosystems investor relations, T2 Biosystems investors, T2 Biosystems losses, T2 Biosystems ppm, T2 Biosystems private placement, T2 Biosystems prospectus, T2 Biosystems recovery options, T2 Biosystems risk, T2 Biosystems stock information, T2 Biosystems update Last modified: December 10, 2019